Evommune, Inc. - 8-K Filing
Evommune reported Q1 2026 financial results with $307.0 million in cash, cash equivalents, and investments as of March 31, 2026, up from $216.7 million in December 2025. The company recorded $0 in revenue for the quarter, down from $3.0 million in Q1 2025, and reported a net loss of $21.7 million, compared to $14.6 million in the same period last year. The filing also highlighted key clinical milestones, including upcoming Phase 2b top-line data for EVO756 in chronic spontaneous urticaria (June 2026) and atopic dermatitis (Q3 2026), and plans to initiate a Phase 2b trial for EVO756 in migraine... (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $EVMN